Tegoprazan Medicine 04 June 2026 Extended indication Tegoprazan monotherapy for treatment of erosive oesophagitis in adults and elderly. Therapeutic value Total cost Registration phase Clinical trials Product Active substance Tegoprazan Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Bowel diseases Extended indication Tegoprazan monotherapy for treatment of erosive oesophagitis in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer HK inno Portfolio holder Mechanism of action Other, see general comments Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Werkingsmechanisme: Kaliumcompetitieve zuurblokker (P-CAB) Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP Submission date June 2026 Expected Registration July 2027 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05587309 (TRIUMpH EE) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Nivel Additional remarks In 2024 presenteerden zich ongeveer 80.000 mensen zich bij de huisarts met slokdarmklachten. Expected cost per patient per year Cost References Additional remarks Er is nog niets bekend over de mogelijke prijs. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks